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Suppression of Peripheral Sympathetic Activity Underlies 
Protease-Activated Receptor 2-Mediated Hypotension
Young-Hwan Kim, Duck-Sun Ahn, Ji-Hyun Joeng, and Seungsoo Chung
Department of Physiology, Yonsei University College of Medicine, Seoul 120-752, Korea
  Protease-activated receptor (PAR)-2 is expressed in endothelial cells and vascular smooth muscle 
cells. It plays a crucial role in regulating blood pressure via the modulation of peripheral vascular 
tone. Although some reports have suggested involvement of a neurogenic mechanism in PAR-2-induced 
hypotension, the accurate mechanism remains to be elucidated. To examine this possibility, we 
investigated the effect of PAR-2 activation on smooth muscle contraction evoked by electrical field 
stimulation (EFS) in the superior mesenteric artery. In the present study, PAR-2 agonists suppressed 
neurogenic contractions evoked by EFS in endothelium-denuded superior mesenteric arterial strips but 
did not affect contraction elicited by the external application of noradrenaline (NA). However, thrombin, 
a potent PAR-1 agonist, had no effect on EFS-evoked contraction. Additionally, ω -conotoxin GVIA 
(CgTx), a selective N-type Ca2+ channel (ICa-N) blocker, significantly inhibited EFS-evoked contraction, 
and this blockade almost completely occluded the suppression of EFS-evoked contraction by PAR-2 
agonists. Finally, PAR-2 agonists suppressed the EFS-evoked overflow of NA in endothelium-denuded 
rat superior mesenteric arterial strips and this suppression was nearly completely occluded by ω -CgTx. 
These results suggest that activation of PAR-2 may suppress peripheral sympathetic outflow by 
modulating activity of ICa-N which are located in peripheral sympathetic nerve terminals, which results 
in PAR-2-induced hypotension.
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INTRODUCTION
  Protease-activated receptor (PARs) are a group of G-pro-
tein coupled receptors (GPCRs) with seven transmembrane 
domains. To date, four members of the PAR family (PAR 
1-4) have been identified [1]. The activation of PARs by pro-
teases involves cleavage of the amino terminal sequence of 
the PAR extracellular N-terminal domain at specific sites. 
The new N-terminus exposed by cleavage acts as a ‘tethered 
ligand’ and binds to a site located in the second ex-
tracellular loop, triggering G-protein coupling and intra-
cellular cell signaling.
  Recently, it has been reported that PAR-2 is highly ex-
pressed on endothelial cells and in vascular smooth muscle, 
suggesting a crucial role in regulating vascular tone [2-5]. 
PAR-2 activation by receptor-activating peptides suppresses 
blood pressure in anesthetized rats or mice in vivo [6-11]. 
This hypotension is only partially inhibited by L-NAME, 
suggesting that a nitric oxide (NO)-independent mechanism 
and a NO-dependent mechanism are involved in the hypo-
tension induced by PAR-2 activation [6,12]. In addition, hy-
potension induced by PAR-2 activation is maintained for 
around 2∼3 min and the ganglion-blocking agent chlor-
isondamine significantly increases the duration of hypo-
tension induced by PAR-2 activation, suggesting that 
PAR-2-induced hypotension may be maintained by modu-
lating peripheral sympathetic tone [8,9,13]. However, a de-
tailed mechanism for the prolonged duration of PAR-2-in-
duced hypotension has not yet been elucidated. 
  It is well documented that voltage-gated N-type Ca2+ 
channels (ICa-N) play an important role in regulating periph-
eral sympathetic tone in postganglionic sympathetic neu-
rons [14,15]. In fact, the decrease in blood pressure acti-
vates a peripheral sympathetic reflex. This enhanced pe-
ripheral sympathetic output increases Ca2+ influx through 
ICa-N located in peripheral sympathetic nerve terminals, 
that in turn triggers the release of noradrenaline (NA) from 
peripheral sympathetic nerve terminals. Therefore, any 
substance that modulates ICa-N activity can affect NA re-
lease from peripheral sympathetic nerve terminals and sig-
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nificantly alter sympathetic tone. It is therefore possible 
that PAR-2-mediated hypotension is associated, in part, 
with the inhibition of peripheral sympathetic output by 
modulating ICa-N that are located on sympathetic nerve 
terminals. 
  To investigate this hypothesis, we examined the effects 
of PAR-2 activation on contraction evoked by electrical field 
stimulation (EFS) in superior mesenteric arterial strips, 
which represents peripheral vascular contraction mediated 
by an increase in peripheral sympathetic output. We also 
examined the effects of PAR-2 agonists on EFS-evoked NA 
outflow to determine the effect of PAR-2 activation on NA 
release on peripheral sympathetic nerve terminals. Our re-
sults demonstrate that PAR-2 may induce hypotension by 
suppressing peripheral vascular sympathetic tone via the 
modulation of ICa-N located in peripheral sympathetic nerve 
terminals in rat SCG neurons. 
METHODS
Animals used
  Male Sprague-Dawley (SD) rats were used in all of the 
experiments conducted. All procedures were performed in 
accordance with protocols approved by the Institutional 
Animal Care and Use Committee of Yonsei University 
Health System (approval reference number: 2014-0052). 
Measurement of isometric tension in rat mesenteric 
artery strips
  Mesenteric artery strips were prepared from Male SD 
rats (250∼350 g), as described previously [16]. Rats were 
deeply anesthetized with isoflurane (3%, 2∼3 min) ad-
ministered by inhalation in a closed chamber. To avoid un-
intended PAR-2 activation by coagulation factors in blood, 
we removed the blood from blood vessels by perfusing the 
rat transcardially with cold Dulbecco’s phosphate buffer 
saline (D-PBS, composition given in the Supplementary in-
formation) for 15 min under the maintained isoflurane 
anesthesia. Next, the first and second branches of the mes-
enteric arteries were excised and helical strips of these ar-
teries were prepared. To avoid possible influences of endo-
thelium-derived factors, the endothelium of the strips was 
removed by gentle rubbing of the endothelial surface with 
forceps. Endothelium-denuded superior mesenteric arterial 
strips were used in all of the isometric contraction measure-
ment performed. The ends of the tissue strip were tied with 
thin threads. One end was connected to a force-displace-
ment transducer to monitor muscle tension and the other 
end was attached to a tissue holder. Strips were bathed 
in Krebs-Henseleit (KH) solution maintained at 37oC and 
were continuously aerated with 95% O2 and 5% CO2. 
Muscle strips were stretched passively to impose 700 mg 
on the resting length and equilibrated for 60 min.
EFS
  Most of the arterial segments were placed between stim-
ulating electrodes made of platinum. Square wave pulses 
of 5 V with a duration 0.2 ms were delivered at a frequency 
of 1 Hz in 10 s trains at 5 min intervals [17-19]. The stim-
ulus pulses were delivered using PowerLab (ADInstru-
ments, Colorado Springs, CO). 
NA assay
  Rat mesenteric artery strips were preincubated for 30 
min in 1 ml of KHS at 37oC and continuously gassed with 
a 95% O2∼5% CO2 mixture (stabilization period). Samples 
of the superfusion Krebs solution were collected before the 
EFS and during the EFS. Then, the tissue segments were 
superfused with drug for 30 min before EFS. Samples were 
frozen in liquid nitrogen and stored at −70oC until the as-
say was performed. To measure the release of noradrenalin, 
we used a noradrenaline research EIA (Labor Diagnostica 
Nord, Gmbh & Co., KG, Nordhon, Germany).
Preparation of superior cervical ganglion neurons
  Superior cervical ganglion neurons (SCG) neurons were 
enzymatically dissociated according to a previously de-
scribed, modified method [19]. The neurons were plated on 
poly-l-lysine-coated 12 mm glass cover slips and incubated 
in a humidified incubator with 95% air, 5% CO2. Neurons 
were used within 12 h after plating.
Electrophysiology
  Voltage-gated Ca2+ currents (ICa) were recorded using 
conventional whole-cell techniques. Electrode resistances 
varied from 3∼5 MΩ when filled with internal solution. 
Measurements were performed using an Axopatch 200 A 
patch-clamp amplifier (Molecular Devices, Sunnyvale, CA). 
Voltage and current commands and the digitization of 
membrane voltages and currents were controlled using a 
Digidata 1322 A interfaced with Clampex 10.2 of the 
pClamp software package (Molecular Devices, Sunnyvale, 
CA), on an IBM-compatible computer. Data was analyzed 
using Clampfit (Molecular Devices, Sunnyvale, CA) and 
Prism 5.0 (GraphPad, San Diego, CA). The cells were 
moved from the incubator to a recording chamber, vi-
sualized using an inverted microscope, and subjected to 
voltage clamp experiments, using the whole cell technique. 
Currents were low-pass filtered at 2 kHz using the four-pole 
Bessel filter of the amplifier. Capacitance (Cm) values were 
automatically calculated during recordings by the pClamp 
10.2 software. Multiple independently controlled syringes 
served as reservoirs for a gravity-driven fast drug perfusion 
system. Switching between solutions was accomplished by 
manually controlled valves. All experiments were con-
ducted at room temperature.
Solutions and drugs
  The Krebs-Henseleit solution (KH solution) of the follow-
ing composition as modified by Asano et al (in mM) [20] 
: 119 NaCl, 4.6 KCl, 2.5 CaCl2, 1.2 KH2PO4 1.2, 1.5 MgSO4, 
25 NaHCO3, 11 glucose. The KH solution was continuously 
aerated with 95% O2 and 5% CO2. The internal (pipette) 
solution contained the following (in mM): 140 CsCl2, 1.2 
MgCl2, 4 MgATP, 0.4 Na2GTP, 10 phosphocreatine, 10 
HEPES, and 10 EGTA; the solution was adjusted to pH 
7.2 with CsOH. The external (bath) solution contained (in 
mM) 155 tetraethylammonium (TEA)-Cl, 2.5 CaCl2, 1.2 
MgCl2, 14 glucose, and 10.5 HEPES; the solution was ad-
justed to pH 7.4 with TEA-OH. ω-conotoxin GVIA (CgTx) 
was purchased from Alomone (Alomone Laboratories, 
Jerusalem, Israel). SLIGRL-NH2 (SL-NH2, a synthetic 
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Fig. 1. Effect of PAR-2 agonists on EFS-induced contraction in 
endothelium-denuded rat superior mesenteric arterial strips. (A) 
a representative trace of inhibition of EFS-induced contraction by 
application of 30 nM trypsin (left) or 30 nM BT (right) (B) a 
representative trace of inhibition of EFS-induced contraction by 
application of 100μM SL-NH2 (left) or LR-NH2 (right) (C) sum-
marized time course of trypsin (0.17±0.04 g for control, 0.10±0.03
g for trypsin, n=6, p＜0.05) or BT (0.9±3.5% inhibition; 0.10±0.02
g for control, 0.10±0.03 g for BT, n=6, p＞0.05) effects on 
EFS-induced contraction. (D) summarized time course of SL-NH2
(0.11±0.04 g for control; 0.07±0.01 g for SL-NH2, n=6, p＜0.05) or 
LR-NH2 (2.6±3.1% inhibition; 0.6±0.1 g for control; 0.6±0.1 g for 
LR-NH2, n=6, p＞0.05) effects on EFS-induced contraction. (E) 
right, Concentration-response curves for trypsin. Left Concen-
tration-response curves for SL-NH2.
PAR-2 agonist peptide) and LRGILS-NH2 (control peptide 
with s reverse sequence) [21] were purchased from COSMO 
Genetech (COSMO Genetech Inc., Seoul, Korea). All other 
drugs were purchased from Sigma-Aldrich Chemicals. All 
drugs were dissolved in distilled water as stock solutions 
(1∼100 mM). 
Data analysis
  Data are presented as the means±SEM, with the number 
of experiments given within parentheses. The concen-
tration-response curves of trypsin and SR-NH2 for ICa in-
hibition were calculated by fitting to a single-site binding 
isotherm with least-squares nonlinear regression using 
Prism 5.0 (GraphPad, San Diego, CA). We used unpaired 
Student’s t-tests to compare data from two groups. Differen-
ces were considered statistically significant at p＜0.05.
RESULTS
Characteristics of EFS-evoked contractions in endo-
thelium-denuded rat superior mesenteric arterial 
strips
  The contractile ability of the preparation was tested by 
perfusing a segment of the arterial strips with a 70 mM 
high-K＋ solution (equimolar substitution of Na＋ with K＋) 
(data not shown). To avoid the possible influences of endo-
thelium-derived factors, the endothelium of the strip was 
removed by gentle rubbing of the endothelial surface with 
a forceps. The efficiency of this method was measured by 
the lack of relaxation elicited by acetylcholine in NA-con-
tracted arteries (Supplmental Fig. 1).
  As shown in Supplmental Fig. 1, EFS evoked contraction 
in superior mesenteric arterial strips. The contraction 
evoked by EFS was completely blocked by 1μM TTX, a po-
tent Na＋ channel blocker, and 1μM prazosin, an α1-se-
lective adrenergic antagonist [22,23]. This indicates that 
the EFS-evoked contractions of the superior mesenteric ar-
terial strips is neurogenic, and mediated via the release of 
NA from sympathetic nerve endings, leading to the activa-
tion of α1-adrenoceptors in vascular smooth muscle (Suppl-
mental Fig. 1A and B) [24,25]. In addition, 1μM ω-CgTx, 
a selective ICa-N blocker [24], suppressed significantly EFS- 
evoked contraction by 65.7±1.8%, suggesting a predominant 
role for ICa-N in regulation of peripheral sympathetic vas-
cular tone (Supplmental Fig. 1C).
PAR-2 agonists suppress EFS-evoked contraction in 
endothelium-denuded rat superior mesenteric arterial 
strips 
  We examined the effects of PAR-2 agonists on the con-
tractions of rat superior mesenteric arterial strips elicited 
by EFS. As shown in Fig. 1A and C, trypsin (30 nM) re-
duced the amplitude of EFS-evoked contractions by 44.1± 
5.4%. However, 30 nM boiled trypsin (BT) didn’t have any 
effect on the contraction evoked by EFS in superior mesen-
teric arterial strips (Fig. 1A and C). Likewise, 100 μM 
SL-NH2, a potent PAR-2 activating peptide, decreased con-
traction amplitude by 41.9±6.8% (Fig. 1B and D). However, 
100μM LR-NH2, a control reverse peptide, had little influ-
ence on the amplitude of EFS-evoked contractions in supe-
rior mesenteric arterial strips (Fig. 1B and D). The IC50 
of trypsin on EFS-evoked contractions was 8.6±3.3 nM (Fig. 
1E). Additionly, the IC50 of SL-NH2 was 32.2±4.5μM (Fig. 
1E). The concentrations at which trypsin and SL-NH2 in-
hibited EFS-evoked contractions sub-maximally were about 
30 nM and 100μM, respectively. These concentrations, 
therefore, were used in all subsequent experiments. 
  To exclude the possibility that the inhibition of EFS-con-
traction by PAR-2 agonists was mediated by direct in-
hibition of vascular smooth muscle contraction, we inves-
tigated the effects of PAR-2 agonists on contraction evoked 
by externally applied NA in endothelium-denuded superior 
mesenteric arterial strips. As shown in Fig. 2, externally 
applied NA (1μM) evoked contractions of endothelium-de-
nuded superior mesenteric arterial strips. Trypsin (30 nM) 
failed to affect the contraction evoked by externally applied 
NA (Fig. 2A, B). Likewise, SL-NH2 (100μM) had no effect 
on the NA-induced contraction (Fig. 2C, D). For comparison, 
we investigated the effects of thrombin, a potent PAR-1 ago-
nist on EFS-induced contraction. Thrombin (30 nM), did not 
show any effects on EFS-evoked contraction in endothe-
lium-denuded superior mesenteric arterial strips 
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Fig. 2. Effect of NA and of NA plus PAR-2 agonists on the response 
to EFS-induced contraction in endothelium-denuded superior 
mesenteric arterial strip. (A) A representative trace of trypsin (30 
nM) effect on the contraction evoked by externally applied NA (1μM). 
(B) Summary of trypsin effect on NA-evoked vasoconstriction 
(0.55±0.13 g for NA, 0.53±0.13 g for NA＋trypsin, n=5, p＞0.05). 
(C) A representative trace of SL-NH2 (100μM) effect on the 
contraction evoked by externally applied NA (1μM). (D) Summary 
of SL-NH2 effect on NA-evoked vasoconstriction (0.7±0.05 g for NA; 
0.66±0.03 g for NA＋SL-NH2, n=5, p＞0.05).
Fig. 3. Effects of ω-CgTx on inhibitory effect of PAR-2 agonists 
on EFS-induced contraction in rat endothelium-denuded superior 
mesenteric arterial strips. (A) A representative trace of the effects 
induced by consecutive application of ω-CgTx (1μM) and trypsin 
(30 nM) on EFS-induced contraction. (B) Summary of ω-CgTx 
effect on trypsin-induced inhibition of EFS-induced contraction (ω- 
CgTx; 65.0±2.9%, ω-CgTx＋trypsin; 62.2±3.2%, p＞0.05, n=5). (C) 
A representative trace of the effects induced by consecutive appli-
cation of ω-CgTx (1μM) and SL-NH2 (100μM) on EFS-induced 
contraction. (D) Summary of ω-CgTx effect on SL-NH2-induced 
inhibition of EFS-induced contraction (ω-CgTx; 66.4±2.3%, ω-CgTx
＋SL-NH2; 60.6±2.3%, p＞0.05, n=5).
Fig. 4. Effect of PAR-2 agonist on EFS-evoked overflow of NA in 
endothelium-denuded rat superior mesenteric arterial strips. (A) 
summary of the effects of trypsin (7.1±0.2 pq/ml for control, 6.0±0.3
pq/ml for trypsin, n=4, p＜0.001), SL-NH2 (7.0±0.3 pq/ml for control; 
6.1±0.2 pq/ml for SL-NH2, n=4, p＜0.001), BT (6.2±0.2 pq/ml for 
control, 6.3±0.2 pq/ml for BT, n=4, P＞0.05), or LR-NH2 (6.7±0.2
pq/ml for control; 6.8±0.2 pq/ml for LR-NH2, n=4, p＞0.05) on the 
EFS-evoked overflow of NA in rat superior mesenteric arterial 
strips. (B) summary of ω-CgTx effect on trypsin or SL-NH2-induced 
inhibition of EFS-evoked overflow of NA in rat superior mesenteric 
arterial strips (ω-CgTx; 17.6±0.5%, ω-CgTx＋trypsin; 17.7±1.1%,
p＞0.05, n=4), (ω-CgTx; 16.1±0.6%, ω-CgTx＋SL-NH2; 15.8±1.2%,
p＞0.05, n=4).
(Supplmental Fig. 2). These results suggest that EFS- 
evoked contraction is suppressed not by PAR-1, but by 
PAR-2 activation and that the suppression by PAR-2 activa-
tion, may be mediated by inhibiting the peripheral sym-
pathetic neuronal output that regulates peripheral vascular 
sympathetic tone. These results suggest that EFS-evoked 
contraction is suppressed by PAR-2 activation and that the 
suppression by PAR-2 activation may be mediated by in-
hibiting the peripheral sympathetic neuronal output that 
regulates peripheral vascular sympathetic tone.
The inhibitory effect of PAR-2 agonists on EFS-evoked 
contraction is mediated by ICa-N
  The SCG neurons contribute to regulating the peripheral 
vascular sympathetic tone of superior mesenteric artery 
[26]. We first performed immunoblotting to confirm the 
presence of PAR-2 protein in SCG neurons. Consistent with 
previous data [27], expression of PAR-2 protein, with a pre-
dicted weight of 52 kDa, was identified in rat lung tissue, 
but was not detected in rat liver tissue. In addition, im-
munoreactivity of PAR-2 protein was also detected, indicat-
ing the presence of PAR-2 protein in rat SCG neurons 
(Supplmental Fig. 3).
  To determine whether ICa-N are involved in the inhibition 
of EFS-evoked contraction by PAR-2 agonists, we examined 
the effect of ω-CgTx on inhibition of EFS-evoked con-
tractions by PAR-2 agonists. Similar to the experiments in 
Supplmental Fig. 1C, ω-CgTx (1μM) suppressed 
EFS-evoked contraction in superior mesenteric arterial 
strips (Fig. 3). The pretreatment with ω-CgTx (1μM) near-
ly completely occluded the inhibitory effect of trypsin on 
EFS-evoked contraction (Fig. 3A and B). Similarly, SL-NH2 
did not affect EFS-evoked contraction in the presence of 
1μM ω-CgTx (Fig. 3C, D), suggesting that inhibition of 
EFS-evoked contraction by PAR-2 activation may be due 
to the modulation of ICa-N located in peripheral sympathetic 
nerve terminals. 
PAR-2 agonists suppress the EFS-evoked overflow of 
NA in endothelium-denuded rat superior mesenteric 
arterial strips 
  We examined the effects of PAR-2 agonists on the 
EFS-evoked overflow of NA in superior mesenteric arterial 
strips. As shown in Fig. 4A, 30 nM trypsin reduced the 
EFS-evoked overflow of NA by 14.9±1.9%. However, 30 nM 
boiled trypsin (BT) did not have any effect on the 
EFS-evoked overflow of NA in superior mesenteric arterial 
strips (Fig. 4A). Likewise, 100 μM SL-NH2 decreased the 
EFS-evoked overflow of NA by 13.2±1.2% (Fig. 4A). On the 
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Fig. 5. PAR-2 agonists inhibited ICa in rat SCG neurons (A) Left, 
a representative trace of ICa in the presence (●) and absence (○) 
of 30 nM typsin. Right, a representative trace of ICa in the presence 
(●) and absence (○) of 30 nM BT. (B) Left, a representative traces 
of ICa in the presence (●) and absence (○) of 100μM SL-NH2. 
Right, a representative trace of ICa in the presence (●) and absence 
(○) of 100μM LR-NH2. (C) left, a summary of ICa inhibition by 
trypsin (815.5±104.9 pA for control; 428.0±54.1 pA for trypsin, n=5) 
and BT (906.6±115.7 pA for control, 863.1±125.6 pA for BT, n=5, 
p＞0.05). Right a summary of ICa inhibition by SL-NH2 (902.5±111.6
pA for control, 506.1±58.8 pA for SL-NH2, n=5) or LR-NH2
(786.8±67.1 pA for control, 727.1±71.2 pA for LR-NH2, n=5, p＞
0.01).
contrary, 100μM LR-NH2, a control reverse peptide, had 
no influence on the EFS-evoked overflow of NA in superior 
mesenteric arterial strips (Fig. 4A).
  To determine whether ICa-N are involved in the inhibition 
of EFS-evoked overflow of NA by PAR-2 agonists, we exam-
ined the effect of ω-CgTx on inhibition of EFS-evoked over-
flow of NA by PAR-2 agonists. ω-CgTx (1μM) suppressed 
EFS-evoked overflow of NA by 16.9±0.4% (6.7±0.1 pq/ml for 
control; 5.6±0.1 pq/ml for ω-CgTx, n= 8, p＜0.001) (Fig. 4B). 
The pretreatment with ω-CgTx (1μM) nearly completely 
occluded the inhibitory effect of trypsin on EFS-evoked 
overflow of NA (Fig. 4B). Similarly, SL-NH2 did not affect 
EFS-evoked overflow of NA in the presence of 1μM ω- 
CgTx (Fig. 4B).
PAR-2 agonists inhibit ICa in rat SCG neurons
  To determine the relationship between PAR-2 and N-type 
voltage-gated Ca2+ channels directly, we examined the ef-
fects of PAR-2 agonists on ICa using the conventional volt-
age-clamp method in dissociated SCG neurons. To measure 
ICa in rat SCG neurons, the current was evoked by 200 ms 
depolarizing step pulses to a test potential of 0 mV from 
a holding potential of −80 mV. The average membrane ca-
pacitance of the CG neurons was 30.6±0.3 pF (n=56). Fig. 
5A shows a typical example of the effect of trypsin on the 
ICa in SCG neurons. Application of 30 nM trypsin dimin-
ished ICa by 45.5±1.7% in an irreversible manner (Fig. 5A 
and C). Likewise, 100μM SL-NH2 also decreased ICa by 
43.6±2.2% in an irreversible (Fig. 5B and C). BT (30 nM) 
(Fig. 5A and C) did not affect the ICa (inhibition 5.6±1.9%). 
Similarly, 100μM LR-NH2 (Fig. 5B and C) did not affect 
ICa (inhibition 8.0±2.8%).
DISCUSSION
  The present study demonstrates that PAR-2 agonists 
suppress neurogenic contraction evoked by EFS by modu-
lating peripheral sympathetic tone, which regulates periph-
eral vascular contractility in endothelium-denuded superior 
mesenteric arterial strips. We also found that the sup-
pression of peripheral sympathetic tone by PAR-2 activa-
tion is mediated mainly by modulating ICa-N located in sym-
pathetic nerve terminals. 
  Since Al-Ani et al. [2] first reported that PAR-2 agonists 
caused an endothelium-dependent relaxation in rat aortic 
rings in nitric oxide (NO)-dependent manner, PAR-2 activa-
tion has been reported to play an important role in regulat-
ing blood pressure in various vascular tissues such as por-
cine coronary arteries [28,29], rat femoral artery [6,30], rat 
pulmonary arteries [30] and basilar arteries [30,31]. 
However, in all of these cases, including resistance vessels, 
PAR-2-induced vasorelaxation was partially maintained 
even after inhibition of NO synthase by L-NAME, suggest-
ing the involvement of another mechanism, distinct from 
the L-Arginine/NO pathway in PAR-2-induced hypotension. 
Consistent with in vitro data, it has been seen with in vivo 
preparations that PAR-2 agonist peptides applied by intra-
venous injection, causes hypotension in anesthetized rats 
[6,7] and mice [9,10]. This PAR-2-induced hypotension is 
also partially inhibited by L-NAME, suggesting the involve-
ment of an NO-independent mechanism [6,8]. In addition, 
this hypotension is not affected by alterations in kidney or 
heart function, suggesting an effect of the PAR-2 agonist 
peptides on the peripheral vascular system [6,9]. These re-
sults therefore suggest that another mechanism, other than 
the NO pathway in endothelium, may be involved in hypo-
tension induced by PAR-2 activation. 
  Neural regulation of blood pressure is accomplished by 
regulating peripheral vascular resistance through the pe-
ripheral sympathetic nervous system. The postganglionic fi-
bers of the peripheral sympathetic nervous system in-
nervate the arteries and arterioles, regulating peripheral 
vascular contraction. NA release from sympathetic nerve 
terminals following peripheral sympathetic activation in-
creases the resistance of peripheral blood vessels via vaso-
constriction of vascular smooth muscle. In normal physio-
logical states, the peripheral sympathetic outputs to blood 
vessels are tonically active and therefore any substance, 
which can alter peripheral sympathetic activity, can readily 
regulate peripheral vascular resistance, which in turn af-
fects blood pressure. So, it is possible that PAR-2 activation 
may regulate blood pressure by modulating activity of pe-
ripheral sympathetic neurons which innervate peripheral 
resistant vasculature. In addition, PAR-2-induced hypo-
tension is quite sustained, lasting about 2∼3 min, com-
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pared to the duration of PAR-1-induced hypotension [6,8,9] 
and the duration of PAR-2-induced hypotension is sig-
nificantly prolonged by ganglion-blockage with chlorisond-
amine [8], suggesting that the regulation of peripheral sym-
pathetic activity by PAR-2 activation, may be involved in 
PAR-2-induced hypotension.
  In the present study, PAR-2 agonists suppressed neuro-
genic contractions evoked by EFS, which mimics vaso-
constriction mediated by peripheral sympathetic activation 
in endothelium-denuded superior mesenteric arterial strips. 
The PAR-2 agonists did not affect contraction elicited by 
the external application of NA. On the contrary, thrombin, 
a potent PAR-1 agonist, had no effect on EFS-evoked con-
traction in endothelium-denuded superior mesenteric arte-
rial strips, suggesting a lack of peripheral sympathetic in-
volvement in PAR-1-induced hypotension. These results 
may explain the difference of time course for between 
PAR-1 and PAR-2 mediated hypotension. 
  As for the pathphysiological function of PAR-2 on blood 
pressure, PAR-2 usually is activated by serine protease 
such as trypsin or trytase which is mainly released from 
endothelial cells and other cells during inflammation [32] 
or coagulation factor XI which is massively activated by tis-
sue factor released by endotoxin in septic condition [33]. 
Therefore, PAR-2 is usually considered to be involved in 
regulation in blood pressure in pathological state. But, re-
cently, McGuire et al., [34] reported that PAR knockout 
mice exhibited moderated elevation of systolic arterial and 
pulse pressure, suggesting PAR-2 involvement in blood 
pressure regulation in normal physiological states. But, fur-
ther studies are needed to elucidate a detailed mechanism 
and functional role for PAR-2-induced hypotension in nor-
mal physiological states.
  ICa-N play an important role in modulating peripheral 
sympathetic activity in postganglionic sympathetic neurons 
[14,15]. Increase in intracellular Ca2+ concentration due to 
Ca2+ influx through voltage-gated Ca2+ channels triggers 
NA release in peripheral sympathetic nerve terminals. 
Therefore, any substance that modulates Ca2+ channel ac-
tivity can influence NA release and therefore regulate pe-
ripheral sympathetic tone [35]. Therefore, PAR-2-mediated 
inhibition of peripheral sympathetic output may be asso-
ciated with ICa-N activity in sympathetic nerve terminals. 
In the present study, the blockade of ICa-N with ω-CgTx 
nearly completely occluded the suppression of EFS-evoked 
contraction by PAR-2 agonists. Consistent with patch- 
clamp data, PAR-2 agonists suppressed the EFS-evoked 
overflow of NA in endothelium-denuded rat superior mes-
enteric arterial strips, which was nearly completely oc-
cluded by ω-CgTx. To determine the effect of PAR-2 ago-
nists on N-type Ca2+ channels in the peripheral sympathetic 
neurons more directly, we tested the effect of PAR-2 ago-
nists on ICa using voltage-clamp in rat SCG neurons which 
regulate peripheral sympathetic tone of the mesenteric 
vasculature. As shown in Fig. 5, PAR-2 agonists diminished 
ICa in an irreversible manner in rat SCG neurons.These re-
sults suggest that the suppression of peripheral sym-
pathetic activity by PAR-2 agonists is mediated mainly by 
the inhibition of ICa-N located in peripheral sympathetic 
nerve terminals.
  In conclusion, the present findings demonstrate that the 
activation of PAR-2 suppresses peripheral sympathetic out-
flow by modulating ICa-N activity located in peripheral sym-
pathetic nerve terminals, which appear to be involved in 
PAR-2-induced hypotension. These results demonstrated, 
for the first time, a possible neuronal mechanism for PAR- 
2-induced hypotension and provide a basic and theoretical 
framework that could lead to the development of new 
agents for the treatment of hypertension.
SUPPLEMENTARY MATERIALS
  Supplementary data including one figure can be found 
with this article online at http://pdf.medrang.co.kr/paper/ 
pdf/Kjpp/Kjpp018-06-07-s001.pdf
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Supplementary information 
Method 
Western blot analysis 
CG, liver, and lungs from rats were rapidly removed, immediately frozen in liquid nitrogen and 
stored at −80°C until used. The homogenates were prepared from these samples. Samples were lysed 
in buffer, which contained Complete Miniprotease inhibitors. The protein concentration was 
determined using a Bradford protein assay kit (Bio-Rad, Hercules, CA). An aliquot containing 100 μg 
of protein from the total lysate was electrophoresed on a 10% SDS-PAGE gel and then transferred to 
Immobilon-P (Millipore, Bedford, MA). After blocking with 5% nonfat dry milk in Tris-buffered 
saline (TBS), the membrane was incubated with a PAR-2 antibody (Santa Cruz Biotechnology Inc., 
Dallas, TX) at an appropriate dilution overnight, at 4°C, and then washed four times in TBS-Tween 
(TBS-T). The membrane was then incubated with a goat anti-mouse Ig (Thermo scientific, Waltham, 
MA) at a dilution of 1:5,000 at room temperature for 1 h and then again washed four times in TBS-T. 
The blots were visualized using ECL reagents (Thermo scientific, Waltham, MA). 
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Supply Fig. 1. Characteristics of EFS-induced contraction in endothelium-denuded superior 
mesenteric arterial strip. (A) a representative trace of the effect of 1 μM TTX on EFS-induced 
contraction. (B) a representative trace of the effect of 1 μM ω-CgTx on EFS-induced contraction (0.1 
± 0.01 g for control, 0.03 ± 0.00 g for ω-CgTx, n = 6). (C) a representative traces of effect of 1 μM 
prazosin on EFS-induce contraction. 
 
Supply Fig. 2. Effect of PAR-1 agonist (Thrombin) on EFS-induced contraction in endothelium-
denuded superior mesenteric arterial streps. (A) a representative trace of  thrombin (30 nM) effect 
on EFS-induced contraction. (B) Time course of thrombin effect on on EFS-induced contraction ( 0.1 
± 0.01 g for control; 0.1 ± 0.02 g for thrombin, n = 6, P > 0.05 ). 
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Supply Fig. 3. Western Immunoblots demonstrating PAR-2 expression in coeliac ganglia neurons. 
Immunoblots for PAR-2 (52 KD). Lung was used as positive control and liver used as a negative 
control. Tissue of origin is showed below each lane. 
 
 
 
 
 
 
 
